|
|
 |
 |
Search Results for: R |
 |
|
 |
|
|
 |
| 16 |
Rosiglitazone Maleate
Manus Aktteva offers Rosiglitazone Maleate, 155141-29-0,for your requirements of RND, evaluation and pilots along with supportive technical package required for evaluation.
View Detail
| List of Intermediates
|
 |
|
|
| 17 |
Rosuvastatin calcium
Manus Aktteva offers Rosuvastatin calcium,147098-20-2, for your requirements of RND along with its intermediates with supportive technical package required for evaluation for intermediates.
View Detail
| List of Intermediates
|
 |
|
|
| 18 |
Rotigotine hydrochloride
Manus Aktteva offers Rotigotine hydrochloride
, 125572-93-2 for RND and its intermediates for your evaluation,pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
| List of Intermediates
|
 |
|
|
| 19 |
(+)-(3R,4R)-3,4-Dimethyl-4-(3-hydroxyphenyl) piperidine
Manus Aktteva offers Alvimopan intermediate (+)-(3R,4R)-3,4-DIMETHYL-4-(3-HYDROXYPHENYL) PIPERIDINE, having cas no, 119193-19-0,for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evalu....
View Detail
|
 |
|
|
| 20 |
(1R,2S)-Pyrrolidin ylnorephedrine
Manus Aktteva can offer (1R,2S)-Pyrrolidin ylnorephedrine, 56571-84-7, for your evaluation, pilots and commercial requirements with supportive technical package required for evaluation
View Detail
|
 |
|
|
| 21 |
(1R,2S,3R,4S)-2,3,4-trihydroxy-1-cyclopentylamine,hydrochloride
Manus Aktteva offers (1R,2S,3R,4S)-2,3,4-trihydroxy-1-cyclopentylamine,hydrochloride, Intermediate of Ticagrelor,for your evaluation,pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
|
 |
|
|
| 22 |
(1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxamide
Manus Aktteva offers Saxagliptin Intermediate,700376-57-4, (1R,3S,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxamide,for your evaluation,pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
|
 |
|
|
| 23 |
(1R,3s,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane
Manus Aktteva offers Maraviroc Intermediate,423165-07-5,(1R,3s,5S)-3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octane,for your evaluation,pilots and commercial requirements with supportive technical package required for evaluati....
View Detail
|
 |
|
|
| 24 |
(2R,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol
Manus Aktteva offers Tapentadol Intermediate,175590-76-8, (2R,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol, for your evaluation,pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
|
 |
|
|
| 25 |
(2R,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol hydrochloride
Manus Aktteva offers Tapentadol Intermediate,175774-12-6, (2R,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol hydrochloride, for your evaluation,pilots and commercial requirements with supportive technical package required for evaluatio....
View Detail
|
 |
|
|
| 26 |
(2R,3R)-3-(3-Methoxyphenyl)-N,N-2-trimethylpentanamine
Manus Aktteva offers Tapentadol Intermediate,175591-22-7, (2R,3R)-3-(3-Methoxyphenyl)-N,N-2-trimethylpentanamine, for your evaluation,pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
|
 |
|
|
| 27 |
(2R,3R)-3-Chloro-3-(3-methoxyphenyl)-N,N-2-trimethylpentanamine
Manus Aktteva offers Tapentadol Intermediate,175591-21-6, (2R,3R)-3-Chloro-3-(3-methoxyphenyl)-N,N-2-trimethylpentanamine, for your evaluation,pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
|
 |
|
|
| 28 |
(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol
Manus Aktteva offers 142217-78-5, Entecavir hydrate Intermediate,(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanol, for your evaluation,pilots and commercial requi....
View Detail
|
 |
|
|
| 29 |
(2R,4R)-1-[(2S)-5-[[Imino(nitroamino)methyl]amino]-2-[[(3-methyl-8-quinolinyl)sulfonyl]amino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid
Manus Aktteva offers Argatroban Intermediate,74874-10-5,(2R,4R)-1-[(2S)-5-[[Imino(nitroamino)methyl]amino]-2-[[(3-methyl-8-quinolinyl)sulfonyl]amino]-1-oxopentyl]-4-methyl-2-piperidinecarboxylic acid, for your evaluation, pilots and commercial requir....
View Detail
|
 |
|
|
| 30 |
(2R,4R)-4-Methylpiperidine-2-carboxylic acid
Manus Aktteva offers 74892-81-2,the intermediate of Argatroban,for your evaluation, pilots and commercial requirements with supportive technical package required for evaluation.
View Detail
|
 |
|
|
|
|
|
|
|
 |
NOTE:
- Manus Aktteva, India is successfully representing suppliers, manufacturers from INDIA, suppliers, manufacturers from CHINA, and fulfilling the requirements of buyers from EUROPE, USA, South America, Japan, Korea, Taiwan, Australia, & middle-east.
Keywords: New Molecules, patents, R&D, cas, cas number, product, supplier, suppliers, vendor, vendors, price, prices, api, apis, active pharmaceutical ingredient, ingredients, importer, exporter, distributor, import, export, sale, producer, manufacturer, synthesizer, synthesis, gmp, cgmp, fda, dmf, cgmp, cos, inventory, stock, prompt shipment, compounding, compound, research, development, patent, r and d, pharma
- Please note that products falling in to controlled substance category shall be exported directly from the manufacturer principals only against receipt of original import permission issued by concerned authorities of the importing country.
Product enquiries may please be sent to info@manusaktteva.in, udeetjbanker@gmail.com, jdbanker@gmail.com
PATENTS:
- => Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
=> Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)
|
|
|
|
|